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Research in context panel 
Evidence before this study 
Intermittent treatment of malaria during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) 
is an essential component of malaria control in sub-Saharan Africa. With the spread of SP-
resistant malaria, there is an urgent need to identify an alternative to SP for the prevention of 
malaria in this vulnerable population. On 18 Feb 2018, we searched MEDLINE, Embase and the 
Cochrane Central Register of Controlled Trials for clinical trials investigating malaria preventive 
treatment during pregnancy. We used the search strategy: (Malaria AND pregnan* AND 
intermittent) AND (prevent* OR prophyla* OR presumpt* OR chemoprevent* OR 
chemoprophyla* OR IPT*) AND (placental OR histo* OR Pathology OR malaria OR birth weight 
OR LBW OR preterm or premature) AND (randomised or clinical or controlled or trial) AND 
(sulfadoxine and pyrimethamine) without restricting publication language or date.  
The search strategy yielded 189 articles. Six studies assessed chloroquine or its combinations 
but none demonstrated evidence of superiority against SP-IPTp. Five chloroquine studies were 
conducted in the context of widespread chloroquine resistance but the absence of SP 
resistance. This is the opposite pattern of what is currently observed in Malawi and the 
surrounding region. A multicentre trial that assessed IPTp with a fixed-dose combination of 
chloroquine and azithromycin compared to IPTp with SP showed equivalence between the two 
interventions but many of the study sites still had high rates of chloroquine-resistant malaria.  
Apart from mefloquine, which was poorly tolerated, the only other candidates with demonstrated 
efficacy superiority over SP-ITPp are artemisinin-based combination therapies (ACTs). 
However, these drugs may not be suitable replacements for SP. ACTs are the first line 
treatment for malaria so the very widespread use of these drugs for prevention may lead to the 
emergence and spread of resistance, thus threatening malaria-endemic countries’ ability to treat 
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those suffering from malaria disease. In addition, the safety of artemisinins in the first trimester 
of pregnancy has not been definitively established, ACTs may not be the ideal replacement for 
SP. 
Therefore, an efficacious, safe, and well-tolerated alternative to SP-IPTp has not been 
definitively identified. With new drug regimens being studied, we might also consider whether 
continuous prophylaxis is preferable to intermittent curative dosing for the prevention of malaria 
and its adverse outcomes during pregnancy.  
Added value of this study 
With the return of chloroquine susceptible malaria in Malawi and throughout the region, we had 
a unique opportunity to evaluate chloroquine, administered either as IPTp or weekly prophylaxis 
compared to IPTp with SP. In our study, chloroquine given as IPTp (two treatments of 
chloroquine 600mg on day one, 600mg on day two, and 300mg on day 3 at least four weeks 
apart), or given as prophylaxis (chloroquine 600mg at enrolment followed by 300mg once every 
week up to delivery), did not demonstrate superior protection from placental malaria, clinical 
malaria, low birth weight, or maternal anaemia than SP-IPTp (two doses of 1500 mg SP given at 
least 4 weeks apart).  However, due to an observed background incidence of 15.4% rather than 
the expected 40%, statistical power was lower than we had anticipated.  Our protocol-specified 
adjusted analyses found that chloroquine as weekly prophylaxis provided modest protection 
against malaria during pregnancy and was more effective than SP-IPTp in preventing placental 
malaria infection among women who did not have malaria infection at enrolment, but do not 
show evidence that chloroquine as IPTp was superior to SP-IPTp. Our study reaffirmed the 
safety and tolerability profile of chloroquine. Although chloroquine arms had more adverse 
events than SP-IPTp overall, it did not increase the risk of severe and life-threatening events, 
and treatment discontinuation was rare. 
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Implications of all the available evidence 
The role of chloroquine as a potential replacement for SP for the prevention of malaria during 
pregnancy remains to be fully established. However, as the search for alternative regimens 
continues, chloroquine prophylaxis needs to remain an important consideration for future trials 
perhaps in higher transmission settings. The unique characteristics making chloroquine a highly 
desirable option include the increasing radius of chloroquine-susceptible malaria in Africa, the 
long half-life and the safety and tolerability. Chloroquine also has advantage over artemisinin 
combination therapies and SP because it can be used in the first trimester, and there is 
increasing evidence that protecting pregnant women as early as possible in pregnancy, when 
many of the placental infections are being established, is likely to be beneficial. 
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Abstract 
Background 
Sulfadoxine-pyrimethamine (SP) resistance threatens efficacy of intermittent preventive 
treatment during pregnancy (IPTp) and there is an urgent need to identify alternative regimens. 
With the return of chloroquine efficacy in Southern Africa, we hypothesized that chloroquine 
either as IPTp or as chemoprophylaxis would be more efficacious than SP-IPTp for prevention 
of pregnancy malaria and associated maternal and newborn adverse outcomes. 
Methods 
We conducted an open label, single-centre randomized clinical trial of chloroquine prophylaxis 
(600mg day-1, 300mg weekly), chloroquine-IPTp (2 doses of 600mg day-1, 600mg day-2, 
300mg day-3)  or SP-IPTp (2 doses), to HIV negative first and second gravid women at 20 to 28 
weeks gestation, in Malawi. Participants were randomly assigned to receive SP-IPTp, 
chloroquine-IPTp, and chloroquine-prophylaxis in a 1:1:1 ratio. We used a computer-generated 
randomization list. Our primary endpoint was placental malaria in participants in the modified 
intent-to-treat population, comprised of those who were randomized and contributed 
histopathology data at birth. ClinicalTrials.gov registration: NCT01443130.  
Findings 
From 2012-2014 we randomized 900 women, 765(85%) contributed histopathology data and 
were included in the analysis. 14% (108/765) experienced placental malaria, which was lower 
than the anticipated rate of placental malaria infection. Our primary analysis did not find 
improved protection from placental malaria by chloroquine as prophylaxis (relative risk (RR) 
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0.75 [95% confidence interval (CI): 0.48, 1.17]), or as IPTp (RR 1.00 [95% CI: 0.67, 1.50]) 
compared to SP-IPTp. However, our protocol specified adjusted analysis of the primary 
outcome found that, women taking chloroquine-prophylaxis experienced 36% lower placental 
infections than those in SP-IPTp arm (RR 0.64 [95% CI: 0.44, 0.93]). Incidence of clinical 
malaria, maternal anaemia and low birth weight was not improved by the interventions.  There 
were nine cases of clinical malaria in the SP-IPTp group, four in the chloroquine IPTp group (p = 
0.26) and two in the weekly chloroquine group (p = 0.06).  There were five cases of maternal 
anaemia in the SP-IPTp group, fifteen in the chloroquine IPTp group (p = 0.04) and six in the 
weekly chloroquine group (p = 1.00).  There were 31 cases of low birth weight in the SP-IPTp 
group, 29 in the chloroquine IPTp group (p = 0.78) and 41 in the weekly chloroquine group (p = 
0.28).  Compared to SP-IPTp both chloroquine arms had more related adverse events overall, 
but there was no difference in severe or life-threatening events.  Adverse events possibly 
related to study product were experienced by four maternal subjects in the SP-IPTp group, 94 in 
the chloroquine IPTp group (p < 0.001) and 26 in the weekly chloroquine group (p < 0.001).  
There were three maternal subjects who experienced severe or life threatening adverse events 
related to study product.  These were all in the chloroquine IPTp group (p = 0.25). 
 
Interpretation 
Chloroquine administered as IPTp did not provide better protection from malaria and related 
adverse effects than SP-IPTp in this setting of high SP-resistance.  Protocol-specified adjusted 
analyses suggest that chloroquine chemoprophylaxis may provide benefit in protecting against 
malaria during pregnancy. 
 
Funding 
U.S. National Institutes of Health 
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INTRODUCTION 
Malaria remains one of the most common infectious diseases in sub-Saharan Africa. Pregnant 
women are uniquely susceptible to malaria because infected erythrocytes sequester in the 
placenta. Placental malaria infection is associated with maternal anaemia and infant low birth 
weight.1 In sub-Saharan Africa, previous studies demonstrated that up to 40% of pregnant 
women develop placental malaria.1  
Although malaria during pregnancy can have significantly impact the health of pregnant women 
and their newborns, it is often asymptomatic and difficult to detect by point-of-care diagnostic 
methods.2 Most malaria-endemic countries recommend intermittent preventive treatment in 
pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) during the second and third trimesters.  
SP-IPTp has been shown to diminish the risk of malaria-associated poor pregnancy outcomes 
but the emergence of SP-resistant malaria is threatening its efficacy hence the urgent need to 
find replacement.3  
In determining an alternative to SP-IPTp, a new drug regimen may provide intermittent 
treatment, as SP did, or provide chemo-prophylaxis to continuously suppress blood stage 
infection. Chemoprophylaxis is usually administered at lower doses than curative regimens and 
may permit the persistence or recurrence of low-level parasitaemia that, in pregnant women, 
could allow for placental sequestration.4 In contrast, IPTp with a full curative dose of an 
efficacious drug, may clear infections in all compartments, but would allow recurrent peripheral 
and placental infection during subsequent infections, especially where transmission rates are 
high. If infection followed by reliable clearance reverses any adverse effect of placental malaria, 
then effective IPTp may be as beneficial as preventing all infections. However, given rapid foetal 
development, even a limited period of acute inflammation and placental dysfunction may 
adversely impact growth. The maternal and foetal impact of IPTp and chemoprophylaxis have 
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not been compared because most clinical trials employ different drugs and differences in 
outcomes are often attributed to variability in the efficacy of the drugs. We had the unique 
opportunity to conduct a study to elucidate the impact of IPTp vs. chemo-prophylaxis in Malawi.  
 
Chloroquine has well-established dosing regimens for both prophylaxis and treatment,5 making 
it one of the few drugs capable of comparing the difference between these two approaches. 
Chloroquine, owing to extensive use in connective tissue disorders and for malaria prevention, 
has a well-documented safety and tolerability profile in pregnancy.6  However, its use for both 
prevention and treatment was suspended due to widespread resistance in the 1980s and 
1990s.7 The return of chloroquine-susceptible malaria in Malawi8  allows us to evaluate the 
potential role of chloroquine in preventing malaria during pregnancy and associated adverse 
outcomes. The results will ultimately impact malaria policy throughout Africa as the return of 
chloroquine-susceptible malaria is being reported in Zambia, Tanzania and Senegal. 9-11 
 
 
We hypothesized that chloroquine-IPTp or chloroquine chemoprophylaxis would be superior to 
SP-IPTp in preventing placental malaria infection and the maternal and newborn adverse effects 
of pregnancy-associated malaria. We therefore performed a randomized controlled clinical trial 
of chloroquine as IPTp or chloroquine as weekly prophylaxis independently compared to SP-
IPTp. Our primary outcome was incidence of placental malaria and our secondary aims included 
incidence of peripheral malaria infection, clinical malaria illness and maternal and infant adverse 
outcomes.  
 
METHODS 
Study design 
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Our study was a three-arm, phase 3, open label, randomized controlled clinical trial comparing a 
weekly prophylactic dose of chloroquine (chloroquine-prophylaxis) and two curative doses of 
chloroquine (chloroquine-IPTp) to SP-IPTp at Ndirande Health Center, Blantyre, southern 
Malawi.12 Malaria infection prevalence in Blantyre at the time of the study  was 9% in the peak 
season13 and SP resistance was widespread.14  
 
The University of Maryland, Baltimore Institutional Review Board, University of Malawi, College 
of Medicine Research and Ethics Committee, and the Malawi Pharmacy, Medicines and 
Poisons Board reviewed and approved the study protocol and informed consent forms. We 
obtained written informed consent from each participant prior to conducting any study 
procedures.  
 
Study participants 
Pregnant women were eligible if they were in their first or second pregnancy, before the 27th 
week of gestation, attending their first antenatal clinic visit, not yet taken routine SP IPTp, willing 
to deliver at either the Ndirande Health Centre or Queen Elizabeth Central Hospital in Blantyre, 
and hoped to remain in the area until 14 weeks after delivery. We excluded women who were 
HIV infected, receiving any chronic therapy with antimalarial or antifolate drugs, had high risk 
pregnancies requiring regular supervision of an obstetrician or with known allergies to study 
drugs. During screening, we evaluated symptomatic women and deferred enrolment if they had 
clinical malaria illness until after treatment and resolution. We used ultrasound to estimate 
gestational age at enrolment.  
 
Randomization and masking 
Participants were randomly assigned to receive SP-IPTp, chloroquine-IPTp, and chloroquine-
prophylaxis in a 1:1:1 ratio. We used a computer-generated block randomization list (blocks of 
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sizes three and six) prepared by a statistician based at the Statistical and Data Coordinating 
Center (SDCC) who had no contact with either the participants or study staff caring for the 
participants. The treatment assignments were concealed using scratch cards adjacent to 
sequentially listed participant identification numbers. 
 
Those assessing the histopathology and molecular results were blinded to treatment 
assignments but study participants, clinical staff and the SDCC team were not.  
 
Procedures 
Participants in the SP-IPTp group received 1,500 mg sulfadoxine and 75 mg pyrimethamine 
(Fansidar, Micro Labs,India) twice at least four weeks apart during pregnancy. In the 
chloroquine-IPTp group, participants received two treatments of chloroquine (ARALEN®, West-
Ward Pharmaceutical Corporation, United States) given as 600mg on day one, 600mg on day 
two, and 300mg on day 3 at least four weeks apart during pregnancy. Participants in the 
chloroquine-prophylaxis group received 600mg of chloroquine at enrolment followed by 300mg 
once every week up to delivery.  
 
We administered all study treatments under directly observed therapy and from 20 and 28 
weeks gestation based on ultrasound scan. For each foetus, the trained ultrasonographer 
averaged two sets of biometric measurements to estimate the gestational age. A perinatologist 
provided training and routine quality control.  
 
We saw participants at least once every four weeks until delivery, then at 2, 6, 10 and 14 weeks 
postdelivery. We encouraged participants to attend the study clinic when they had health 
complaints. We attempted to trace participants who failed to attend appointments. At each 
routine or sick visit, we obtained a comprehensive history including malaria symptoms and 
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routine obstetric complaints, followed by clinical examination, and management of any ailments. 
At all routine visits, we collected a dried blood spot on filter paper and measured haemoglobin 
concentration (HemoCue). At any visit during which participant had symptoms suggestive of 
malaria, we prepared and read thin and thick blood smears to facilitate clinical management. 
We obtained placental biopsies, placental impression smears, and cord blood from deliveries 
that occurred at the Ndirande Maternity Ward and Queen Elizabeth Central Hospital.  
 
For microscopic detection of malaria infection from the thin and thick blood smears, we stained 
them with Giemsa stain and two microscopists(MK, RM and others) read them independently to 
detect the presence of Plasmodium parasites. If their readings were discordant, the slide was 
read by a third expert reader. For molecular detection of malaria infection, we extracted DNA 
from the filter paper dried blood spots and performed quantitative real-time PCR evaluation for 
Plasmodium falciparum 18S rRNA using University of Maryland malaria research program 
standard procedures.15 We performed pyrosequencing on cases of malaria infection detected at 
enrolment to determine the P. falciparum chloroquine resistance transporter genotype at 
positive 76, the molecular marker for chloroquine-susceptibility.15  We did not analyse resistance 
to SP because it is ubiquitous in Malawi and surrounding countries.14  
 
For histopathological analysis, we cut the paraffin wax-preserved placental biopsies into four 
micron thick sections, applied them to glass slides, and then stained with hematoxylin and 
eosin. The histopathologist based at the University of Malawi, College of Medicine evaluated 
placental slides for malaria pigment (hemozoin) and malaria parasite to determine acute, 
chronic or past infection defined as visible parasites but little or no definitive pigment, presence 
of parasites and pigment, and presence of pigment in the absence of parasites respectively (see 
examples in Appendix). Ten percent of all the placental slides underwent quality control by a 
histopathologist based at the Centers for Disease Control and Prevention.  
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Outcomes 
Our primary endpoint was histologically confirmed placental malaria defined as the presence of 
hemozoin or parasites on a placental biopsy specimen. We also used the outcome of placental 
malaria measured by either histological or molecular evidence of infection as a secondary 
definition of placental malaria. Our secondary outcomes were peripheral malaria infection, 
clinical malaria illness, and adverse outcomes associated with malaria in pregnancy. We 
recorded episodes of peripheral malaria infection and clinical malaria illness between enrolment 
and delivery dates. 
 
We defined clinical malaria illness as malaria infection on blood smear in a participant with any 
one of the following; fever (axillary temperature ≥37·5OC) measured at the clinic, history of fever 
in the past 48 hours or other symptoms (headache, myalgia, vomiting or weakness) in the last 
48 hours. We defined a new case as a clinical malaria episode occurring at least 14 days after 
the last treatment day of the previous episode. When a maternal clinical malaria illness was 
diagnosed, we treated the participant according to Malawi national guidelines: they received 
quinine if in the first trimester and artemether-lumefantrine if in the second or third trimesters. 
We defined malaria infection as detection of parasites by microscopy or PCR regardless of 
symptoms. We defined baseline malaria infection as malaria infection at the enrolment visit.  
 
The malaria adverse effects we evaluated included incidence of maternal anaemia 
(haemoglobin concentration < 10 g/dL), maternal severe anaemia (haemoglobin concentration < 
7g/dL), stillbirth and miscarriage (pregnancy loss before and after 28 weeks gestation, 
respectively), preterm delivery (delivery before 37 weeks gestation), low birth weight (birth 
weight less than 2500g), intrauterine growth restriction (IUGR, weight <10th percentile 
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gestational age based on the WHO foetal growth curve), and early infant mortality (death before 
14 weeks of age).  
 
Statistical analysis 
We calculated the sample size to provide 80% power assuming a 40% incidence of histology-
determined placental malaria for women receiving SP-IPTp and a reduction of 33% in either 
chloroquine treatment arm. Since two separate hypothesis tests were required (i.e., comparing 
SP-IPTp to each treatment arm), We based the sample size calculation on a two-sided test for 
difference in proportions with a normal approximation, which led to an estimate of 237 
participants per arm, accounting for the Bonferroni correction so each p-value was compared to 
an alpha of 0·025. Assuming that 20% of enrolled mothers would not contribute a primary 
outcome, we reached a target sample size of 300 per arm, or 900 in total.  
 
 
We performed the primary analysis using a modified intention-to-treat (mITT) approach that 
included all randomized women who contributed placental histology results in the groups to 
which they were randomized, regardless of the amount of treatment received. We also 
performed a per-protocol (PP) analysis, excluding any participants who received non-study SP, 
who were lost to follow-up before delivery, who did not contribute histology results, or who were 
non-compliant in terms of their allocated treatment arm (missing any dose for chloroquine-IPTp 
and SP-IPTp arms, or missing 4 or more doses for chloroquine-prophylaxis arm).  
 
For the a priori primary analysis, relative risks of placental malaria in each treatment arm were 
calculated relative to the SP-IPTp group, and p-values were calculated using Fisher’s exact test. 
Our secondary outcome, placental malaria detected by histopathology or by qPCR, was 
analysed in the same way.  
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Our protocol also specified an adjusted analysis of the primary outcome including any of the 
following potential confounding variables, which are known predictors of placental malaria:16-19 
maternal age, gravidity status, gestational age at enrolment, low body mass index (BMI) (< 18·5 
kg/m2), enrolment during malaria transmission season, use of an insecticide-treated bed net the 
night before enrolment, baseline anaemia (haemoglobin < 10 g/dL at enrolment), and baseline 
malaria infection status.  Covariates whose relative risks with the outcome had p-values < 0·10 
were included in a multivariable model.  As an exploratory analysis, we expanded the model to 
examine interactions between each covariate and treatment assignment.  In the expanded 
model, baseline malaria was the sole covariate whose interaction with at least one treatment 
variable was statistically significant at the 0·10 level (p = 0.046 in the mITT population). For this 
reason, we proceeded to fit a model stratified on baseline malaria status.  This model is a post-
hoc analysis as we had not anticipated any covariate-treatment interactions.  We estimated 
coefficients for the adjusted and stratified models using modified Poisson regression.20  
 
For our secondary outcomes, we compared relative risks of peripheral malaria and clinical 
malaria infection between treatment arms in the intention-to-treat population (including all 
mothers who were randomized). We also fit Kaplan Meier curves and performed log rank tests 
comparing time to malaria infection and time to clinical malaria between treatment arms. 
 
We assessed safety and tolerability by comparing unsolicited adverse events between arms 
from the date the first study product was administered through the final study visit. We graded 
adverse events depending on severity as defined in the Division of Microbiology and Infectious 
Diseases (DMID) adult toxicity table of November 2007. Adverse events were listed as mild 
(grade 1) if they required minimal or no treatment and did not interfere with the patient’s daily 
activities; moderate (grade 2) if they resulted in a low level of inconvenience often interfering 
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with functioning and requiring minor intervention; Severe (grade 3) if they interrupted usual daily 
activity and often requiring systemic drug therapy or other treatment; or Life-Threatening (grade 
4) if they placed the participant at immediate risk of death.  
 
When reporting each adverse event, we determined based on known properties of the study 
products, whether the event was causally related to any of the trial treatments. All participants 
who received treatment and contributed safety data were included in these analyses. We 
performed analyses using SAS version 9.4 (SAS Institute, USA) and R version 3.4.0. 
 
A Data and Safety Monitoring Board (DSMB) with expertise in clinical trials, malaria in Africa, 
and biostatistics provided safety oversight. The DSMB reviewed safety data twice during data 
collection and this included assessment against pre-specified halting criteria. We registered the 
protocol with ClinicalTrials.gov (NCT01443130). 
 
Role of the funding source 
The funder of the study contributed towards the study design, but had no role in data collection, 
data analysis, data interpretation, or writing of this manuscript. The corresponding author had 
full access to all the data in the study and had final responsibility for the decision to submit for 
publication. 
 
RESULTS 
From February 2012 to May 2014, we screened 1,209 women and randomized 900 to receiving 
chloroquine-prophylaxis (n=300), chloroquine-IPTp (n=300), or SP-IPTp (n=300) (Figure 1). 
Eighty-five percent (766/900) of the randomized women provided pregnancy outcome data 
(Figure 1). Of these, 765 contributed histopathology results, and were included in the mITT 
analysis for the primary outcome. One participant missing histopathology results did contribute 
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qPCR results, so was also included in the mITT analysis of the secondary outcome. The PP 
population comprised of 80% (719/900) of the randomized women. Inclusion in the mITT or PP 
populations did not differ significantly between treatment arms. However, women who did not 
contribute a histopathology result tended to be younger at enrolment (19·92 vs. 20·61 years, p = 
0·027), have lower gestational age at enrolment (21·90 vs. 22·30 weeks, p = 0·05), and be 
more likely to have baseline malaria infection (24.44% vs. 18.17%, p=0.087) when compared to 
those who were successfully followed to delivery and included in primary outcome analysis. 
Baseline characteristics of participants are summarized in Table 1, and those for participants in 
the mITT population are in the Appendix, Table A1.  All malaria infections that occurred at 
enrolment were chloroquine-susceptible based on carrying the susceptible form the of the pfcrt 
gene.  
 
Table 2 shows results for our primary and secondary outcomes.  The rate of placental malaria in 
the SP-IPTp arm (15.4%) was much lower than the anticipated rate of 40% that we had used for 
our sample size calculation.  In our primary analysis, the risk of placental malaria detected by 
histopathology among mothers receiving chloroquine-prophylaxis (30/259 [11.6%]) was lower 
than those receiving SP-IPTp (15.4%). The relative risk is 0.75 (95% C.I. [0.48, 1.17]) and is not 
statistically significant (p = 0.24).  The relative risk from the model adjusting for potential 
confounding variables is 0.66 (95% C.I. [0.46, 0.95]) and approaches statistical significance (p = 
0.03, compared to a Bonferroni-adjusted significance level of 0.025).  The adjusted RR for the 
secondary outcome, placental malaria detected by positive histopathology or positive qPCR, 
was 0.64 (95% C.I. [0.46, 0.90]) and was statistically significant (p = 0.01).   We did not find 
evidence that the chloroquine IPTp treatment differed from SP-IPTp in preventing placental 
malaria (Table 2). Results for PP analysis are similar. (Appendix Table A2).  Appendix Tables 
A3 and A4 include full results from the adjusted models (including covariate effects).   
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Table 3 shows that in a stratified model on baseline malaria status, chloroquine-prophylaxis  has 
a stronger protective effect in the subgroup of participants without baseline malaria (RR 0.44; 
95% CI: 0.23, 0.85; p =0.01) compared to the subgroup of those with baseline malaria (RR 0.94 
(95% CI: 0.70, 1.27 p =0.69) (Table 4). Chloroquine-IPTp treatment did not significantly impact 
either subgroup.  In this model, the p-value for the interaction between chloroquine-prophylaxis 
and baseline malaria is 0.04; it is 0.93 for the interaction between chloroquine-IPTp and 
baseline malaria.  Results for the PP analysis are similar (Appendix Table A5). 
 
We recorded 86 malaria infections during follow up, 15 of which were clinical malaria illness. 
There was no difference in the risk of malaria infection or clinical malaria illness by treatment 
arm (Appendix Table A6). Chloroquine-prophylaxis was associated with a longer time to clinical 
malaria illness compared to SP-IPTp (log rank p=0.03). The time to clinical malaria was similar 
for chloroquine-IPTp and SP-IPTp (log rank p=0.17).  There was no difference in time to malaria 
infection between the groups.  
 
Malaria-related prenatal and perinatal outcomes included 168 cases (19%) of anaemia during 
the prenatal period (including 2 severe malaria cases), 26 cases (3%) of anaemia at delivery 
(none was severe), and one maternal death (Table 4). There were more cases of maternal 
anaemia at delivery in the chloroquine-IPTp group (15 cases) compared to the SP-IPTp group 
(5 cases, p=0·04), although the difference is not statistically significant when applying 
Bonferroni-adjusted significance level of 0.025. There were no significant differences between 
arms for prenatal anaemia, severe anaemia, or maternal death.  
 
The overall mean birth weight was 2.89 kg (SD = 0.42 kg) and average gestational age at 
delivery was 38.5 weeks (SD = 2.4 weeks) were similar between treatment arms. The 
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interventions were not associated with the risk of low birth weight, preterm delivery or smallness 
for gestational age (Table 7). 
 
Both chloroquine treatment regimens were associated with higher rates of treatment-related 
adverse events than the SP-IPTp regimen (Table 5). More women in the chloroquine-IPTp (94 
women, p < 0.001) and chloroquine-prophylaxis (26 women, p<0.001) groups experienced at 
least one treatment-related adverse event than those randomized to SP-IPTp arm (4 women). 
The most recorded treatment-related adverse events among women were dizziness, vomiting, 
nausea, palpitations, headache, and abdominal pain. In the SP-IPTp group, 1 woman 
experienced a Grade 2 or higher treatment-related adverse event, compared to 14 women .3% 
vs. 5%, p=0.001) in the chloroquine-prophylaxis group and 57 women (19%, p<0.001) in the 
chloroquine-IPTp group. Five treatment-related adverse events (4 in chloroquine-IPT and 1 in 
chloroquine-prophylaxis arms) led to study treatment termination. No significant differences in 
rates of serious adverse events, between treatment arms were observed. 
 
DISCUSSION 
Our open-label randomized controlled clinical trial provides evidence that chloroquine-
prophylaxis may be more effective than SP-IPTp in reducing placental malaria in healthy 
pregnant women in Malawi. In our primary analysis, we did not find evidence of superior 
protection from histopathology determined placental malaria using either chloroquine-
prophylaxis or chloroquine-IPTp versus the current standard of care, SP-IPTp. Our adjusted 
model found the reduction in placental malaria due to chloroquine-prophylaxis was approached 
significance for the primary measure of placental malaria by histopathology and was statistically 
significant when including placental specimens with molecular evidence of infection. Our post-
hoc stratified model indicated that the effect was strongest among participants without baseline 
malaria. Furthermore, compared with SP-IPTp, chloroquine-prophylaxis offered some protection 
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against clinical malaria illness during pregnancy. Chloroquine-IPTp, however, did not provide 
any benefit compared to SP-IPTp.  
 
Our stratified analysis suggests that chloroquine-prophylaxis may be more effective than SP-
IPTp in preventing new placental malaria infections in pregnant women.  However, in the case 
of existing sequestration of parasites in the placenta, as was the case with women who were 
infected with malaria when they first presented to antenatal care, the prophylactic doses of 
chloroquine did not effectively clear the placental infection. As the findings from our stratified 
model were unanticipated and based on an exploratory analysis, we recommend their validation 
through confirmatory studies which explicitly investigate the effectiveness of a chloroquine 
prophylaxis regimen and whether this effect is modified by baseline malaria infection.   
 
One drawback about the use of chloroquine is the higher rate of drug-related adverse reactions 
compared to SP-IPTp. Most events were mild and dose dependent. The specific complaints and 
also the higher rate in IPTp compared to prophylaxis were similar to previously described 
reactions.21 These complaints rarely resulted in discontinuation of the study treatment. In our 
study adverse events in the chloroquine arms were mostly mild or moderate (grade 1 or 2) and 
rarely led to treatment discontinuation. This experience is different from that evaluation of a 
fixed-dose combination of chloroquine and azithromycin and registered more treatment 
discontinuations in the intervention arm compared to SP-IPTp arm.22 It is possible that the 
intolerance was largely driven by the azithromycin or differences in reporting of safety 
outcomes. This highlights the need for standardized methods for assessing and reporting safety 
data from drug trials In addition, because our study was open-label, participant perception of 
health outcomes may have been influenced by their knowledge of their treatment assignment, 
and bias may have been introduced in clinical care and adverse event reporting.  However, our 
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primary endpoint of placental malaria, especially given the direct observation of study drugs, is 
unlikely to have been impacted by this. 
 
Among the maternal and newborn outcomes of malaria during pregnancy that are measured, 
birth weight is typically considered to be of greatest public health importance. Although we 
found some evidence that chloroquine prophylaxis may be more effective in preventing 
placental malaria than SP-IPTp, there was no impact on infant birthweight. The lack of impact of 
more effective antimalarial drugs on birthweight when compared to SP-IPTp is consistent with 
many recent findings in which dihydroartemisinin-piperaquine and mefloquine IPTp regimens 
were more effective in preventing malaria but their use as IPT was not associated with improved 
birthweight. This suggests that malaria in this setting is not the key driving factor contributing to 
low birthweight or that SP has an impact on birthweight, perhaps through its broad antimicrobial 
activity, that is not limited to malaria.23 
 
Despite high rates of SP resistant malaria in Malawi,14 replacing SP-IPTp with chloroquine-IPTp 
did not provide significantly increased protection against placental malaria, peripheral malaria 
infection or clinical malaria disease. Larger studies in higher transmission settings have 
demonstrated that monthly dosing of drugs that are more effective than SP do lead to lower 
rates of malaria infection and disease.24 Recent studies employing monthly dihyrdroartemisinin-
piperaquine demonstrated better protection from malaria during pregnancy for women receiving 
the intervention than those receiving monthly SP-IPTp.25,26 This suggests that increasing the 
frequency of curative doses from twice during pregnancy to monthly with an effective 
antimalarial may be an even more optimal approach. This study was conducted before Malawi 
adopted the World Health Organization recommendation of giving SP IPTp doses at every 
scheduled antenatal visit in the second and thirrd trimesters, at least one month apart. It is 
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possible that increasing from two to more doses may lead to improved protection against 
malaria infection and disease in the chloroquine-IPT group.  
 
Our study had lower power than planned due to a lower rate of placental malaria in the base 
population (15.4% in SP-IPTp arm) than what we expected during study planning (≥40%). This 
effectively decreased our power to detect the planned difference (≥33%) by 65% (from 80% 
down to 28%). Malaria prevalence among pregnant women at our study site declined over the 
course of the study in association with increased distribution of insecticide-treated bed nets.12  
 
As a drug used for frequent IPTp administration, chloroquine has several advantages over 
dihydroartemisinin-piperaquine. The safety of chloroquine in pregnancy has been well-
established due to its widespread use in auto-immune diseases. Exposure to artemisinin 
compounds during the first trimester is currently not recommended in the World Health 
Organization treatment guidelines due to early embryonic toxicity identified in some animal 
studies.27  
Another key advantage of using chloroquine is avoidance of drug pressure that may promote 
the development of resistance to either the artemisinin compound or its partner drug when 
artemisinin-based combination therapy is used for both IPTp and also for treatment of malaria 
disease in the general population. We have recently demonstrated that SP-resistant malaria in 
Malawi has persisted and even increased in prevalence with the continued use of SP for IPTp 
even after its use for the treatment of malaria was discontinued.14 Although artemisinin 
resistance has not appeared to emerge in Africa,28 its arrival is inevitable. It is unclear if using 
the same or similar drugs for treatment and for IPTp will hasten the emergence or spread of 
resistance. If a drug or drug combination used in IPTp is not simultaneously used for clinical 
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malaria case management, then IPTp may actually lower the selection pressure on the first-line 
drug by decreasing symptomatic cases that require treatment. 
 
In summary, our study did not have enough superiority evidence of chloroquine either as IPTp 
or as chemoprophylaxis versus SP-IPTp for prevention of malaria during pregnancy and 
associated maternal and infant adverse outcomes. This was likely secondary to low event rate 
which reduced our discriminatory power. However, the results of our adjusted analysis and ITT 
safety analyses suggest that chloroquine prophylaxis remains a valuable alternative to SP worth 
re-examining in future trials. Our findings are likely generalizable to much of eastern Africa and 
parts of western Africa where chloroquine-susceptible malaria now predominates. If suppressive 
levels can be maintainedthrough weekly dosing, chloroquine may provide better protection 
against clinical malaria disease in pregnant women and parasite sequestration in the placenta 
than the current standard of care. Most recent studies, with one notable exception, have not 
found that improved malaria prevention was associated with an increase in birthweight.24 While 
birthweight is one of the key public health outcomes to evaluate when identifying a new strategy 
to prevent malaria during pregnancy, additional outcomes for studies should be considered in 
evaluating the need to switch from SP-IPTp to a more effective drug.  
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TABLES AND FIGURES 
FIGURE 1: Study Consort 
Divala TH, Mungwira RG, Mawindo PM, Nyirenda OM, Kanjala M, Ndaferankhande M, Tsirizani LE, Masonga R, Muwalo F, Boudová S, Potter 
GE. Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial. 
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Table 1: Summary of baseline characteristics for all 900 randomized participants 
Covariate 
All Chloroquine 
prophylaxis 
Chloroquine-
IPTp SP-IPTp 
Continuous Covariates Mean (SD) 
Maternal Age at 
Enrolment/Randomization (years) 
20.5 (3.3) 20.4 (3.6) 20.7 (3.2) 20.4 (3.1) 
Gestational Age at Enrolment by 
Ultrasound (weeks) 
22.2 (2.2) 22.5 (2.2) 22.2 (2.2) 22.0 (2.1) 
Categorical Covariates n (%) 
Young Maternal Age at Enrolment/ 
Randomization 
(< 20 Years) 
382 (42) 141 (47) 111 (37) 130 (43) 
Gravidity Status at 
Enrolment/Randomization 
518 (58) 177 (59) 162 (54) 179 (60) 
BMI less than 18.5 kg/m
2
 7 (1) 1 (<1) 2 (1) 4 (1) 
Malaria Transmission Season at 
Enrolment/Randomization 
309 (34) 102 (34) 102 (34) 105 (35) 
Used a bed net the night before 
enrolment 
678 (75) 228 (76) 221 (74) 229 (76) 
Anaemia (Haemoglobin < 10 g/dL) at 
Enrolment/Randomization 
80 (9) 26 (9) 31 (10) 23 (8) 
Malaria Infection at Enrolment/ 
Randomization 
80 (9) 28 (9) 23 (8) 29 (10) 
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Masonga R, Muwalo F, Boudová S, Potter GE. Chloroquine as weekly chemoprophylaxis or 
intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial. The 
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Table 2: Efficacy of interventions on the incidence of placental malaria, modified intent-to-treat population 
n/N (%) 
Relative Risk 
[95% CI] 
P-value
Type of Infection 
Chloroquine 
prophylaxis 
Chloroquine-
IPTp 
SP-IPTp 
Chloroquine 
prophylaxis 
vs. 
SP-IPTp 
Chloroquine-
IPTp 
vs. 
SP-IPTp 
Chloroquine 
prophylaxis 
vs. 
SP-IPTp 
Chloroquine-
IPTp 
vs. 
SP-IPTp 
Positive histopathology 
(primary outcome) 
30/259 (11.6) 39/253 (15.4) 39/253 (15.4) 
0.75 
[0.48, 1.17] 
1.00 
[0.67, 1.50] 
0.24 1.00 
Positive histopathology, 
Adjusted 
- - - 
0.66 
[0.46, 0.95] 
0.99 
[0.69, 1.41] 
0.03 0.94 
Positive histopathology or 
positive qPCR 
34/259 (13.1) 45/254 (17.7) 47/253 (18.6) 
0.71 
[0.47, 1.06] 
0.95 
[0.66, 1.38] 
0.12 0.82 
Positive histopathology or 
positive qPCR, 
Adjusted 
- - - 
0.64 
[0.46, 0.90] 
0.94 
[0.68, 1.32] 
0.01 0.74 
NOTE: The adjusted model includes maternal age, gestational age, and indicators for bednet use the night before enrolment, anaemia at enrolment, 
and malaria infection at enrolment.
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Table 3. Placental malaria (by histology) by treatment arm stratified by baseline malaria, mITT population (adjusted for maternal age, gestational 
age at enrolment, bed net use, anaemia at enrolment) 
Baseline Malaria (n=65) No Baseline Malaria (n=700) 
Variable Estimate 
95% Confidence 
Interval P-value Estimate 
95% Confidence 
Interval P-value
Chloroquine prophylaxis 0.942 (0.700, 1.268) 0.693 0.442 (0.230, 0.848) 0.014 
Chloroquine-IPTp 0.967 (0.692, 1.352) 0.844 0.995 (0.593, 1.672) 0.986 
Maternal Age 0.871 (0.822, 0.923) <0.001 0.902 (0.841, 0.968) 0.004 
Gestational Age (weeks) 0.961 (0.899, 1.026) 0.234 1.103 (0.994, 1.225) 0.065 
Bednet Use, Night before 
Enrollment 
1.050 (0.799, 1.380) 0.725 1.267 (0.774, 2.076) 0.347 
Anaemia at Enrollment 
(Hemoglobin < 10 mg) 
1.368 (1.070, 1.749) 0.013 2.803 (1.638, 4.796) <0.001 
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Table 4: Number and proportion of subjects experiencing malaria-related prenatal and perinatal outcomes by treatment 
group in the intention-to-treat population 
ALL SP-IPTp Chloroquine-
IPTp 
Chloroquine 
prophylaxis 
Chloroquine-IPTp 
vs. SP-IPTp 
Chloroquine prophylaxis 
vs. SP-IPTp 
N % N % N % N % RR 95% CI 
P-
Value 
RR 95% CI 
P-
Value 
Maternal Outcomes 
Prenatal Maternal Anaemia 
(haemoglobin < 10 g/dL) 
168 19 60 20 61 20.3 47 15.7 1.02 (0.74, 1.40) 1 0.783 (0.55, 1.11) 0.200 
Prenatal Severe Maternal 
Anaemia (haemoglobin < 7 
g/dL) 
2 0 1 0.3 1 0.3 0 0 1 (0.11, 9.55) 1 0 (0, 3.83) 1 
Delivery Maternal Anaemia 
(haemoglobin < 10 g/dL) 
26 3 5 1.7 15 5 6 2 3 (1.15, 7.87) 0.038 1.2 (0.39, 3.67) 1 
Delivery Severe Maternal 
Anaemia (haemoglobin < 7 
g/dL) 
0 0 0 0 0 0 0 0 NA NA 1 NA NA 1 
Maternal death 1 0 0 0 1 0.3 0 0 NA NA 1 NA NA 1 
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Infant Outcomes 
Low birth weight (<2.5kg) 101 13 31 12 29 11 41 16 0.91 (0.57, 1.45) 0.784 1.29 (0.84, 1.98) 0.257 
Preterm Delivery (estimated 
gestational age < 37 weeks) 
69 8 18 7 28 10 23 8 1.50 (0.86, 2.63) 0.168 1.25 (0.69, 2.24) 0.518 
IUGR (weight < 10th 
percentile gestational age 
based on WHO foetal growth 
curve) 
142 18 52 21 47 18 43 17 0.87 (0.61, 1.23) 0.435 0.80 (0.55, 1.14) 0.255 
Stillbirth (estimated 
gestational age ≥ 28 weeks) 
9 1 5 2 1 0 3 1 0.19 (0.03, 1.23) 0.117 0.58 (0.16, 2.19) 0.499 
Miscarriage (estimated 
gestational age < 28 weeks) 
6 1 3 1 2 1 1 0 0.64 (0.13, 3.19) 0.681 0.32 (0.05, 2.25) 0.367 
Infant Death (< 14 weeks old) 24 3 8 3 10 4 6 2 1.20 (0.50, 2.92) 0.812 0.73 (0.27, 1.99) 0.598 
NOTE: RR = relative risk 
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Table 5: Number and proportion of maternal subjects experiencing adverse events possibly related to study treatment by 
treatment group and MedDRA Preferred Term 
SP-IPTp 
(N= 300) 
Chloroquine-
IPTp 
|(N= 300) 
Chloroquine 
prophylaxis 
(N= 300) 
Chloroquine-IPTp 
vs. SP-IPTp 
Chloroquine prophylaxis 
vs. SP-IPTp 
n % n % n % RR 95% CI P-value RR 95% CI P-value
Any adverse event 4 1% 94 31% 26 9% 23.5 (9.2, 61.1) <0.001 6.5 (2.4, 17.7) <0.001 
At least one Grade 3 or 
higher adverse event 
0 0% 3 1% 0 0% NA NA 0.249 NA NA 1 
At least two adverse 
events 
1 0% 64 21% 10 3% 64.0 (11.3, 365.5) <0.001 10.0 (1.7, 60.4) 0.011 
Termination of study 
drug due to treatment-
related AE 
0 0% 4 1% 1 0% NA NA 0.124 NA NA 1 
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Dizziness
1
 1 0% 57 19% 7 2% 57.0 (10.1, 326) <0.001 7.0 (1.1, 43.5) 0.068 
Vomiting 0 0% 50 17% 11 4% NA NA <0.001 NA NA 0.001 
Palpitations 1 0% 14 5% 7 2% 14.0 (2.4, 83) 0.001 7.0 (1.1, 43.5) 0.068 
Headache 1 0% 17 6% 2 1% 17.0 (2.9, 100) <0.001 2.0 (0.3, 15.2) 1 
Nausea 2 1% 15 5% 3 1% 7.5 (1.9, 29.3) 0.002 1.5 (0.3, 7.5) 1 
Abdominal pain 0 0% 7 2% 2 1% NA NA 0.015 NA NA 0.499 
NOTE: RR = relative risk 
1 
The six most frequent related events are displayed. 
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Assessed for eligibility
N = 1209
Excluded: N=309
· Ineligible (N=136)
· Disapproval of study participation by
family members (N=112)
· Living outside cachement area during
study period (N=22)
· Not interested (N=8)
· Unable to contact participant (N=5)
· Other (N=26)
Excluded from mITT (N=41)
· Lost to follow-up before
delivery (N=28)
· Did not contribute a
placenta (N=13)
Enrolled and randomized
N=900
Allocated to Chloroquine 
prophylaxis
(N=300)
Excluded from mITT (N=46)
· Lost to follow-up before
delivery (N=27)
· Did not contribute a
placenta (N=19)
Allocated to Chloroquine 
IPTp
(N=300)
Allocated to SP IPTp
(N=300)
Excluded from mITT (N=47)
· Lost to follow-up before
delivery (N=36)
· Did not contribute a placenta
(N=11)Included in 
mITT 
analysis 
(N=259)
Included in PP 
analysis 
(N=243)
Included in 
mITT 
analysis 
(N=254)
Included in PP 
analysis 
(N=227)
Included in 
mITT 
analysis 
(N=253)
Included in PP 
analysis 
(N=249)
Excluded from PP (N=57)
· Missed study product
administration (N=27)
· Received SP outside of
study protocol (N=1)
· Lost to follow-up before
delivery (N=28)
· Did not contribute a
placenta (N=13)
Excluded from PP (N=74)
· Missed study product
administration (N=30)
· Received SP outside of
study protocol (N=1)
· Lost to follow-up before
delivery (N=27)
· Did not contribute a
placenta (N=19)
Excluded from PP (N=51)
· Missed study product
administration (N=2)
· Received SP outside of
study protocol (N=2)
· Lost to follow-up before
delivery (N=36)
· Did not contribute a
placenta (N=11)
Figure 1 Consort Diagram
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Appendix 
Table A1.  Summary of Baseline Characteristics for Participants in the Modified Intent-to-Treat 
Population 
Covariate 
All Treatment 
Groups 
Chloroquine 
Weekly 
Chloroquine 
IPTp SP IPTp 
Continuous Covariates Mean (SD) 
Maternal Age at Enrollment/Randomization 20.6 (3.4) 20.4 (3.7) 20.9 (3.3) 20.5 (3.2) 
Gestational age by ultrasound (weeks) 22.3 (2.2) 22.5 (2.2) 22.3 (2.2) 22.1 (2.1) 
Categorical Covariates n (%) 
Young Maternal Age at Enrollment/Randomization 
(< 20 Years) 
316 (41) 123 (47) 86 (34) 107 (42) 
Gravidity Status at Enrollment/Randomization 438 (57) 154 (59) 135 (53) 149 (59) 
BMI (weight/height2) less than 18.50 5 (1) 1 (<1) 2 (1) 2 (1) 
Malaria Transmission Season at 
Enrollment/Randomization 
265 (35) 87 (34) 89 (35) 89 (35) 
Used a bednet last night 582 (76) 196 (76) 193 (76) 193 (76) 
Anemia (Hemoglobin < 10 mg) at 
Enrollment/Randomization 
70 (9) 25 (10) 26 (10) 19 (8) 
Malaria Infection at Enrollment/Randomization 65 (8) 24 (9) 20 (8) 21 (8) 
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Table A2: Efficacy of interventions on the incidence of placental malaria, per-protocol 
population 
n/N (%) 
Relative Risk 
[95% CI] 
P-value
1
Type of Infection 
Chloroquine 
prophylaxis 
Chloroquine-
IPTp 
SP-IPTp 
Chloroquine 
prophylaxis 
vs. 
SP-IPTp 
Chloroquine-
IPTp 
vs. 
SP-IPTp 
Chloroquine 
prophylaxis 
vs. 
SP-IPTp 
Chloroquine-
IPTp 
vs. 
SP-IPTp 
Positive 
histopathology 27/243 (11.1) 35/226 (15.5) 39/249 (15.7) 
0.71 
[0.45, 1.12] 
0.99 
[0.65, 1.50] 
0.15 
1.00 
Positive 
histopathology, 
Adjusted 
- - - 
0.64 
 [0.44, 0.93] 
0.98 
[0.68, 1.42] 
0.02 0.92 
Positive 
histopathology or 
positive qPCR 
31/243 (12.8) 40/227 (17.6) 46/249 (18.5) 
0.69 
[0.45, 1.05] 
0.95 
[0.65, 1.40] 
0.08 0.91 
Positive 
histopathology or 
positive qPCR 
Adjusted 
- - - 
0.64 
 [0.44, 0.91] 
0.95 
[0.67, 1.34] 
0.01 0.76 
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Table A3.  Efficacy of interventions on the incidence of placental malaria (by histopathology) 
adjusting for baseline characteristics, mITT population 
Univariate analysis, N=765 Multivariable analysis, N=765 
Variable 
Unadjusted RR 
(95% Confidence 
Interval) P-value
Adjusted RR 
(95% Confidence 
Interval) P-value
Chloroquine 
Prophylaxis 
0.75 [0.48, 1.17] 0.244 0.66 [0.46, 0.95] 0.027 
Chloroquine-IPTp 1.00 [0.66, 1.50] 1.000 0.99 [0.69, 1.41] 0.936 
Maternal Age (years) 0.88 [0.83, 0.93] <.001 0.89 [0.84, 0.93] <.001 
Gravidity Status 
(Primagravid) 
1.13 [0.79, 1.61] 0.531 . 
Gestational Age (weeks) 1.07 [0.99, 1.16] 0.080 1.05 [0.98, 1.13] 0.140 
BMI less than 18.50† 0 [0, 3.10] 1.000 . 
Malaria Transmission 
Season 
0.98 [0.68, 1.42] 1.000 . 
Bednet Use, Night 
before Enrollment 
0.69 [0.48, 1.00] 0.068 1.17 [0.85, 1.61] 0.332 
Anemia at Enrollment 
(Hemoglobin < 10 mg) 
3.82 [2.71, 5.38] <.001 2.02 [1.45, 2.80] <.001 
Baseline Malaria 8.30 [6.25, 11.0] <.001 6.43 [4.74, 8.73] <.001 
†Score interval was used due to small cell counts. 
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Table A4.  Efficacy of interventions on the incidence of placental malaria (by histopathology) 
adjusting for baseline characteristics, PP population 
Univariate analysis, N=718 Multivariable analysis, N=718 
Variable 
Unadjusted RR 
(95% Confidence 
Interval) P-value
Adjusted RR 
(95% Confidence 
Interval) P-value
Chloroquine 
Prophylaxis 
0.71 [0.45, 1.12] 0.147 0.64 [0.44, 0.93] 0.021 
Chloroquine-IPTp 0.99 [0.65, 1.50] 1.000 0.98 [0.68, 1.42] 0.924 
Maternal Age (years) 0.88 [0.83, 0.93] <.001 0.88 [0.84, 0.93] <.001 
Gravidity Status 
(Primagravid) 
1.15 [0.80, 1.67] 0.516 . 
Gestational Age (weeks) 1.07 [0.98, 1.16] 0.121 1.05 [0.97, 1.12] 0.215 
BMI less than 18.50† 0 [0, 3.51] 1.000 . 
Malaria Transmission 
Season 
0.99 [0.67, 1.44] 1.000 . 
Bednet Use, Night 
before Enrollment 
0.67 [0.46, 0.99] 0.047 1.17 [0.84, 1.63] 0.342 
Anemia at Enrollment 
(Hemoglobin < 10 mg) 
3.73 [2.61, 5.32] <.001 1.95 [1.39, 2.72] <.001 
Baseline Malaria 7.99 [5.95, 10.7] <.001 6.21 [4.52, 8.53] <.001 
†Score interval was used due to small cell counts. 
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Table A5.  Placental Malaria (by histology) by treatment arm, stratified by baseline malaria, PP 
Population 
Baseline Malaria (n=61) No Baseline Malaria (n=657) 
Variable Estimate 
95% Confidence 
Interval P-value Estimate 
95% Confidence 
Interval P-value
CQ Weekly 0.918 (0.675, 1.248) 0.586 0.431 (0.219, 0.848) 0.015 
CQ IPTp 0.924 (0.645, 1.325) 0.668 1.021 (0.603, 1.728) 0.938 
Maternal Age 0.863 (0.809, 0.920) <0.001 0.899 (0.836, 0.966) 0.004 
Gestational Age (weeks) 0.956 (0.891, 1.027) 0.218 1.095 (0.984, 1.220) 0.097 
Bednet Use, Night before 
Enrollment 
1.081 (0.811, 1.442) 0.594 1.233 (0.744, 2.046) 0.416 
Anemia at Enrollment 
(Hemoglobin < 10 mg) 
1.365 (1.045, 1.783) 0.022 2.613 (1.504, 4.540) <0.001 
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Table A6: Efficacy of interventions on the incidence of malaria infection and clinical 
malaria  
Variable Arm N Events Incidence RR (95% CI) P-value
Intention to treat Malaria infection 
during pregnancy 
SP-IPTp 300 33 33/300 (11.0%) NA NA 
Chloroquine-
IPTp 
300 27 27/300 (9.0%) 0.82 (0.51, 1.32) 0.45 
Chloroquine 
prophylaxis 
300 26 26/300 (8.7%) 0.79 (0.49, 1.28) 0.41 
Clinical malaria 
during pregnancy 
SP-IPTp 300 9 9/300 (3.0%) NA NA 
Chloroquine-
IPTp 
300 4 4/300 (1.3%) 0.44 (0.15, 1.34) 0.26 
Chloroquine 
prophylaxis 
300 2 2/300 (0.7%) 0.22 (0.05, 0.90) 0.06 
Per protocol Malaria infection 
during pregnancy 
SP-IPTp 260 27 27/260 (10.4%) NA NA 
Chloroquine-
IPTp 
243 19 19/243 (7.8%) 0.75 (0.43, 1.31) 0.36 
Chloroquine 
prophylaxis 
254 21 21/254 (8.3%) 0.80 (0.47, 1.37) 0.45 
Clinical malaria 
during pregnancy 
SP-IPTp 260 5 5/260 (1.9%) NA NA 
Chloroquine-
IPTp 
243 1 1/243 (0.4%) 0.21 (0.03, 1.37) 0.22 
Chloroquine 
prophylaxis 
254 2 2/254 (0.8%) 0.41 (0.09, 1.81) 0.45 
NOTE: Malaria infection includes those with positive parasitaemia by blood smear and/or parasitaemia by PCR 
and/or clinical malaria from enrolment day to delivery day. Confidence intervals are score intervals, and p-values 
were calculated with Fisher’s Exact Test. One subject was excluded from the analysis of clinical malaria due to 
missing smear result. 
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Hematoxylin and eosin stained sections of formalin-fixed paraffin-embedded placental tissue.  A)  Uninfected red blood 
cells (RBC) from an uninfected placenta.  Fine pigment precipitate can be seen (arrowheads) which is a processing artifact 
that can be mistaken for parasitized RBC.  B)  Parasitized RBC (arrowheads) in a case of active placental malaria.  C) Malaria 
pigment (hemozoin) (arrowheads) persisting in fibrin in a case of past placental malaria.   
Appendix images placental histopathology
Divala TH, Mungwira RG, Mawindo PM, Nyirenda OM, Kanjala M, Ndaferankhande M, Tsirizani LE, Masonga R, Muwalo F, Boudová S, Potter GE. Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent 
malaria in pregnancy in Malawi: a randomised controlled trial. The Lancet Infectious Diseases. 2018 Oct 1;18(10):1097-107.  doi:10.1016/S1473-3099(18)30415-8
